Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Anceau, C."'
Autor:
Payrat, J. A., Cugnet-Anceau, C., Maillet, D., Levy, M., Raverot, G., Disse, E., Borson-Chazot, F.
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2020, 107 (4), pp.490--498. ⟨10.1016/j.bulcan.2020.01.012⟩
Bulletin du Cancer, John Libbey Eurotext, 2020, 107 (4), pp.490--498. ⟨10.1016/j.bulcan.2020.01.012⟩
International audience; Checkpoint inhibitors immunotherapy is more and more prescribed in oncology, causing new immune related endocrine adverse events. Hypophysitis occurs in approximately 10 % of patients treated with anti-CTLA4. It occurs two to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c755b625267d6571ddf1c31486bf1a5a
https://hal.archives-ouvertes.fr/hal-02901888
https://hal.archives-ouvertes.fr/hal-02901888
Publikováno v:
In Diabetes & Metabolism December 2019 45(6):598-600
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Annales d'Endocrinologie February 2023 84(1):92-93
Publikováno v:
In Materials Science & Engineering B 2005 118(1):28-33
Publikováno v:
In Chemical Physics Letters 2005 411(1):98-102
Publikováno v:
Bulletin du cancer
Bulletin du cancer, 2019, ⟨10.1016/j.bulcan.2019.10.005⟩
Bulletin du cancer, 2019, ⟨10.1016/j.bulcan.2019.10.005⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::04bb08385d299ce78869cda5b29097da
https://hal.archives-ouvertes.fr/hal-02465740
https://hal.archives-ouvertes.fr/hal-02465740
Autor:
Jehl, A., Cugnet-Anceau, C., Vigouroux, C., Legeay, A. L., Dalle, S., Harou, O., Marchand, L., LASCOLS, O., Caussy, C., Thivolet, C., Laville, M., Disse, E.
Publikováno v:
Diabetes Care
Diabetes Care, 2019, 42 (10), pp.2008--2010. ⟨10.2337/dc18-2535⟩
Diabetes Care, 2019, 42 (10), pp.2008--2010. ⟨10.2337/dc18-2535⟩
OBJECTIVE: Anti-programmed cell death-1 (anti-PD-1) antibodies have revolutionized advanced cancer therapy. Anti-PD-1 therapy is responsible for immune-related adverse events, with frequent endocrine manifestations, including acute-onset type 1 diabe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e788ba03e3c8c1bb5c4ddc58b6f951aa
https://hal.archives-ouvertes.fr/hal-02465922
https://hal.archives-ouvertes.fr/hal-02465922
Publikováno v:
In Microelectronics Reliability 2003 43(4):565-569
Autor:
Peiffert, M., Cugnet-Anceau, C., Chikh, K., Dalle, S., Assaad, S., Raverot, G., Borson-Chazot, F., Abeillon-Du Payrat, J.
Publikováno v:
In Annales d'Endocrinologie September 2020 81(4):254-255